224 related articles for article (PubMed ID: 21529846)
1. Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study.
Jennings D; McDonnell J; Schillig J
J Thorac Cardiovasc Surg; 2011 Jul; 142(1):e1-2. PubMed ID: 21529846
[No Abstract] [Full Text] [Related]
2. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
[TBL] [Abstract][Full Text] [Related]
3. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
[TBL] [Abstract][Full Text] [Related]
4. Self-control of long-term oral anticoagulation using a point-of-care device.
Roudaut R
Arch Cardiovasc Dis; 2008; 101(11-12):683-4. PubMed ID: 19059561
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit.
Wong CS; Batchelor K; Bua J; Newall F
Thromb Res; 2011 Oct; 128(4):331-4. PubMed ID: 21620442
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
Saeed O; Shah A; Kargoli F; Madan S; Levin AP; Patel SR; Jermyn R; Guerrero C; Nguyen J; Sims DB; Shin J; D'Alessandro D; Goldstein DJ; Jorde UP
Circ Heart Fail; 2016 Jan; 9(1):e002296. PubMed ID: 26721914
[TBL] [Abstract][Full Text] [Related]
7. Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients.
Dauphin C; Legault B; Jaffeux P; Motreff P; Azarnoush K; Joly H; Geoffroy E; Aublet-Cuvelier B; Camilleri L; Lusson JR; Cassagnes J; de Riberolles C
Arch Cardiovasc Dis; 2008; 101(11-12):753-61. PubMed ID: 19059570
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device.
Henderson JB; Iyer P; Coniglio AC; Katz JN; Chien C; Hollis IB
Pharmacotherapy; 2019 Oct; 39(10):1030-1035. PubMed ID: 31463945
[TBL] [Abstract][Full Text] [Related]
9. Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
Fiore M; James C; Mouton C; Calderon J; Barandon L; Ouattara A; Picard F
J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3119-25.e1. PubMed ID: 25212058
[TBL] [Abstract][Full Text] [Related]
10. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
[TBL] [Abstract][Full Text] [Related]
11. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
12. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
[TBL] [Abstract][Full Text] [Related]
13. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.
Kormos RL; Teuteberg JJ; Pagani FD; Russell SD; John R; Miller LW; Massey T; Milano CA; Moazami N; Sundareswaran KS; Farrar DJ;
J Thorac Cardiovasc Surg; 2010 May; 139(5):1316-24. PubMed ID: 20132950
[TBL] [Abstract][Full Text] [Related]
14. Impact of continuous flow left ventricular assist device on the pharmacodynamic response to warfarin early after implantation.
Jennings DL; Brewer R; Williams C
Ann Pharmacother; 2012 Sep; 46(9):1266-7. PubMed ID: 22932304
[No Abstract] [Full Text] [Related]
15. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.
Nassif ME; LaRue SJ; Raymer DS; Novak E; Vader JM; Ewald GA; Gage BF
Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27154497
[TBL] [Abstract][Full Text] [Related]
16. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation.
Spyropoulos AC
Dis Mon; 2005; 51(2-3):183-93. PubMed ID: 15900271
[No Abstract] [Full Text] [Related]
17. [Long-term oral coagulation. Self monitoring prevents complication].
MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813982
[No Abstract] [Full Text] [Related]
18. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.
Uriel N; Pak SW; Jorde UP; Jude B; Susen S; Vincentelli A; Ennezat PV; Cappleman S; Naka Y; Mancini D
J Am Coll Cardiol; 2010 Oct; 56(15):1207-13. PubMed ID: 20598466
[TBL] [Abstract][Full Text] [Related]
19. [Recommended use of INR in the laboratory monitoring of oral anticoagulant treatment].
Syrjälä M
Duodecim; 1998; 114(6):573-5. PubMed ID: 11466922
[No Abstract] [Full Text] [Related]
20. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0.
Denas G; Cucchini U; Iliceto S; Pengo V
Thromb Haemost; 2009 Feb; 101(2):410-1. PubMed ID: 19190831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
